Medical Devices

The Japanese giant is turning period poverty and gender disparity into a business model, using pads and education to unlock new markets in China, Brazil, and Kenya.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

The new iPSC-derived sensory neurons offer a reproducible human model, aiming to fix the broken pipeline of pain research and accelerate new analgesics.

A novel, non-surgical neuromodulation ring is set for a pivotal trial showcase, offering a potential new first-line therapy for millions of women.

For millions with disabilities, a simple ride is a lifeline. One company is turning a logistical nightmare into a path to independence and essential care.

Biotech firm ImmunoScape partners with a top US cancer center for a novel trial, backed by a strategic investment from actor Leonardo DiCaprio.

A new, smaller implant for back surgery promises easier procedures for surgeons and lasting relief for patients by tackling the risk of reherniation.

Cordis presents pivotal 12-month data for its innovative SELUTION SLR drug-eluting balloon, a device that could change how doctors treat clogged arteries.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

In a booming aesthetics market, one company is enlisting elite surgeons to architect the future of recovery, aiming to close a critical gap in patient care.

Beyond the prescription pad, a new concierge program in Tucson integrates advanced diagnostics and lifestyle coaching to redefine sustainable weight management.

Scientists have supercharged a compound from rice bran, creating a potent new weapon against cellular aging that could reshape the future of nutrition.

As Sera Prognostics preps its year-end report, investors watch to see if its groundbreaking preterm birth test can deliver financial health.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

A new partnership integrates advanced AI for brain lesion tracking into a global imaging network, promising safer Alzheimer's treatments and faster diagnostics.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

With four new partners and a zero-markup model, Harrison.ai's Open Platform aims to democratize access to powerful medical AI tools for providers globally.